Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06455293 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Therapy for Depression in Parkinson's Disease
A Phase 2 study of Depression and Parkinson Disease, sponsored by Joshua Woolley, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06455293: Recruiting Phase 2 study of Depression and Parkinson Disease, sponsored by Joshua Woolley, MD, PhD.
NCT06455293 is a Phase 2 study of Depression and Parkinson Disease that is actively recruiting participants, run by Joshua Woolley, MD, PhD. The registered enrollment target is 60 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06455293, a Phase 2 study of Depression and Parkinson Disease, is actively recruiting participants, sponsored by Joshua Woolley, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Primary Outcome
Changes in depression as measured by the MADRS
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT06455293 shows while recruiting
NCT06455293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT06455293 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06455293 about?
NCT06455293 is a clinical study titled "Psilocybin Therapy for Depression in Parkinson's Disease". The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
What is the current status of trial NCT06455293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-08-19. Estimated completion is 2028-06.
What conditions does trial NCT06455293 study?
This clinical trial studies the following conditions: Depression, Parkinson Disease.
What interventions are being tested in trial NCT06455293?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06455293?
This trial is sponsored by Joshua Woolley, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06455293 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06455293's enrollment target sits among peer trials
60 428th of 679 higher than 234 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy